AUA 2025: Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High Risk Upper Tract Urothelial Carcinoma
AUA 2025, upper tract urothelial carcinoma (UTUC), Tislelizumab, humanized IgG4 anti-PD-1 monoclonal antibody.
Related Articles
AUA 2025: PIVOT-006: A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec Versus Surveillance for the Treatment of Intermediate-Risk NMIBC
AUA 2025, bladder cancer, non-muscle invasive bladder cancer (NMIBC), PIVOT-006 trial, Cretostimogene Grenadenorepvec Versus Surveillance for the Treatment of Intermediate-Risk non-muscle invasive bladder cancer, BCG-unresponsive…
Trump’s first 100 days, seen through 5 lives: Grants terminated. Dreams crushed. Futures in the balance
STAT spoke with people living through the historic disruptions threatening the future of biomedical research in the U.S. These are their stories
AUA 2025: Crossfire: Controversies in Urology: Single Port vs Multiport Robotic Surgery
AUA 2025 single-port vs multi-port robotic surgery, minimally invasive surgery, endourology, robot assisted laparoscopic radical prostatectomy, robot assisted partial nephrectomy.
AUA 2025: Sub-Classification of CHAARTED and LATITUDE Risk Categories: Analysis of the Discrepancy Between High- and Low- Groups: A Multicenter Retrospective Study
AUA 2025 advanced prostate cancer, discrepancy between the CHAARTED and LATITUDE risk categories, metastatic hormone-sensitive prostate cancer (mHSPC).
AUA 2025: Systemic Treatment Prescription and Switch Patterns in mHSPC Based on Real World Evidence: Results from the PIONEER+ Big Data Consortium for Prostate Cancer
AUA 2025 PIONEER+ Big Data Consortium, prostate cancer, systemic treatment prescription and switch patterns, metastatic hormone-sensitive prostate cancer (mHSPC) patients.
Major tuberculosis vaccine trial completes enrollment faster than expected
A closely watched clinical trial testing what could be the world’s first new tuberculosis vaccine in a century has hit its enrollment target, ahead of…
AUA 2025: Postoperative Adjuvant Treatment of HER2-Overexpressing Upper Tract Urothelial Carcinoma with Disitamab Vedotin and Toripalimab: A Real-World Retrospective Study
AUA 2025 HER2-overexpressing upper tract urothelial carcinoma, disitamab vedotin, toripalimab, Radical nephroureterectomy, surgery for urothelial carcinoma.
AUA 2025: Case Discussions in NMIBC: Sequencing Therapy after BCG Failures
AUA 2025 Sequencing Therapy after BCG Failures, full-dose BCG induction course, blue light TURBT, high-risk NMIBC, gemcitabine-docetaxel, pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept.
HHS, RFK Jr. sued again over $11B infectious disease grant cuts as measles threat rises
The Department of Health and Human Services (HHS) and Secretary Robert F. Kennedy Jr. | As concerns about infectious disease outbreaks increase, the HHS is…
